Twist Bioscience Co. (NASDAQ:TWST) Stock Position Lowered by Sei Investments Co.

Sei Investments Co. decreased its position in Twist Bioscience Co. (NASDAQ:TWST) by 4.3% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 296,416 shares of the company’s stock after selling 13,346 shares during the period. Sei Investments Co.’s holdings in Twist Bioscience were worth $13,774,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in TWST. Thrivent Financial for Lutherans boosted its position in shares of Twist Bioscience by 54.6% in the fourth quarter. Thrivent Financial for Lutherans now owns 1,505,753 shares of the company’s stock worth $69,972,000 after buying an additional 532,040 shares during the period. State Street Corp lifted its stake in Twist Bioscience by 19.9% in the 3rd quarter. State Street Corp now owns 3,167,353 shares of the company’s stock worth $143,101,000 after acquiring an additional 526,028 shares in the last quarter. Wellington Management Group LLP boosted its position in Twist Bioscience by 188.5% during the 3rd quarter. Wellington Management Group LLP now owns 797,737 shares of the company’s stock worth $36,042,000 after acquiring an additional 521,272 shares during the period. Jennison Associates LLC grew its stake in Twist Bioscience by 80.2% during the 4th quarter. Jennison Associates LLC now owns 680,778 shares of the company’s stock valued at $31,636,000 after acquiring an additional 302,884 shares in the last quarter. Finally, American Century Companies Inc. increased its holdings in shares of Twist Bioscience by 63.5% in the 4th quarter. American Century Companies Inc. now owns 756,352 shares of the company’s stock valued at $35,148,000 after purchasing an additional 293,751 shares during the period.

Wall Street Analyst Weigh In

TWST has been the subject of several research reports. Barclays set a $58.00 price target on shares of Twist Bioscience and gave the stock an “overweight” rating in a report on Monday, February 3rd. JPMorgan Chase & Co. boosted their price target on shares of Twist Bioscience from $35.00 to $40.00 and gave the company an “underweight” rating in a report on Tuesday, February 4th. Scotiabank reiterated an “outperform” rating on shares of Twist Bioscience in a report on Tuesday, February 4th. Robert W. Baird boosted their target price on Twist Bioscience from $48.00 to $54.00 and gave the company an “outperform” rating in a research note on Tuesday, February 4th. Finally, Wolfe Research started coverage on Twist Bioscience in a research note on Friday, December 13th. They set an “outperform” rating and a $60.00 price target for the company. One analyst has rated the stock with a sell rating, one has given a hold rating and eight have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $54.40.

Twist Bioscience Stock Down 2.9 %

Shares of Twist Bioscience stock opened at $40.36 on Friday. Twist Bioscience Co. has a 12-month low of $27.41 and a 12-month high of $60.90. The stock has a market capitalization of $2.41 billion, a P/E ratio of -11.94 and a beta of 2.15. The company has a quick ratio of 4.62, a current ratio of 4.96 and a debt-to-equity ratio of 0.03. The stock has a 50 day moving average price of $45.15 and a two-hundred day moving average price of $45.33.

Twist Bioscience (NASDAQ:TWST) last posted its earnings results on Monday, February 3rd. The company reported ($0.53) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.62) by $0.09. The business had revenue of $88.70 million for the quarter, compared to analyst estimates of $86.96 million. Twist Bioscience had a negative net margin of 59.76% and a negative return on equity of 32.69%. Twist Bioscience’s revenue was up 24.1% compared to the same quarter last year. During the same period last year, the business posted ($0.75) EPS. Equities analysts expect that Twist Bioscience Co. will post -2.12 earnings per share for the current year.

Insider Activity

In other news, insider Dennis Cho sold 806 shares of the firm’s stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $49.35, for a total value of $39,776.10. Following the sale, the insider now owns 112,221 shares in the company, valued at approximately $5,538,106.35. This trade represents a 0.71 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO Adam Laponis sold 5,886 shares of the company’s stock in a transaction on Friday, January 10th. The shares were sold at an average price of $43.26, for a total transaction of $254,628.36. Following the transaction, the chief financial officer now owns 110,096 shares of the company’s stock, valued at approximately $4,762,752.96. The trade was a 5.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 33,799 shares of company stock valued at $1,593,944. 3.01% of the stock is owned by insiders.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.